| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Thomas Hartung | Q22954575 |
| P2093 | author name string | Enrico Sabbioni | |
| P2860 | cites work | There's plenty of room at the forum: potential risks and safety assessment of engineered nanomaterials | Q23910352 |
| Meeting report: hazard assessment for nanoparticles - report from an interdisciplinary workshop | Q23915211 | ||
| Improved method to disperse nanoparticles for in vitro and in vivo investigation of toxicity | Q23922852 | ||
| Nanomedicine and nanotoxicology: two sides of the same coin | Q24170135 | ||
| Pulmonary applications and toxicity of engineered nanoparticles | Q24650775 | ||
| Nanotoxicology | Q24676412 | ||
| Chemical regulators have overreached | Q27921860 | ||
| Physicochemical factors that affect metal and metal oxide nanoparticle passage across epithelial barriers | Q28384922 | ||
| A 21st century paradigm for evaluating the health hazards of nanoscale materials? | Q28389697 | ||
| In vitro assessments of nanomaterial toxicity | Q28391612 | ||
| Assessing nanotoxicity in cells in vitro | Q28394837 | ||
| Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles | Q29029891 | ||
| Oops they did it again! Carbon nanotubes hoax scientists in viability assays | Q29615573 | ||
| Safe handling of nanotechnology | Q29617531 | ||
| Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. | Q30476027 | ||
| Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop | Q33285010 | ||
| A toxicology for the 21st century--mapping the road ahead | Q33346986 | ||
| Interaction of nanoparticles with cells | Q33488029 | ||
| Widespread intraspecies cross-contamination of human tumor cell lines arising at source. | Q33875830 | ||
| Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli | Q34607367 | ||
| Eradication of cross-contaminated cell lines: a call for action | Q34631369 | ||
| Toxicology for the twenty-first century | Q34991369 | ||
| Toxicity testing in the 21st century: implications for human health risk assessment | Q35456016 | ||
| Problems of somatic mutation and cancer | Q35677655 | ||
| The integrated project ReProTect: a novel approach in reproductive toxicity hazard assessment | Q36130565 | ||
| Nanomedicines and nanotoxicology: some physiological principles | Q36546963 | ||
| Toward an evidence-based toxicology | Q36611279 | ||
| Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery | Q36627043 | ||
| Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. | Q36627730 | ||
| Targeted nanoparticle-based drug delivery and diagnosis | Q36799773 | ||
| Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy | Q36933043 | ||
| Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution | Q37036373 | ||
| Toxicity testing in the 21st century: a vision and a strategy. | Q37037988 | ||
| Nanotoxicity: the growing need for in vivo study | Q37045340 | ||
| Inhaled nanoparticles--a current review. | Q37116123 | ||
| Toxicology. Transforming environmental health protection | Q37185407 | ||
| Current in vitro methods in nanoparticle risk assessment: limitations and challenges | Q37262421 | ||
| The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop | Q37311022 | ||
| Toxicity testing in the 21st century: bringing the vision to life | Q37346896 | ||
| Nanoparticle-cell interactions: drug delivery implications | Q37376371 | ||
| A proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up and Top-Down approaches | Q37505571 | ||
| Development of in vitro systems for nanotoxicology: methodological considerations | Q37570536 | ||
| Genotoxicity and morphological transformation induced by cobalt nanoparticles and cobalt chloride: an in vitro study in Balb/3T3 mouse fibroblasts | Q39824972 | ||
| Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. | Q39921419 | ||
| Bringing toxicology into the 21st century: a global call to action | Q39969584 | ||
| International validation of pyrogen tests based on cryopreserved human primary blood cells. | Q40469295 | ||
| Cell line cross-contamination: how aware are Mammalian cell culturists of the problem and how to monitor it? | Q40473671 | ||
| International validation of novel pyrogen tests based on human monocytoid cells. | Q40510058 | ||
| Cell cross-contamination in cell cultures: the silent and neglected danger | Q41738605 | ||
| The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative | Q42594054 | ||
| Factors stimulating or obstructing the implementation of the 3Rs in the regulatory process | Q42645840 | ||
| ECVAM's ongoing activities in the area of acute oral toxicity | Q42796080 | ||
| Assessment of pyrogenic contaminations with validated human whole-blood assay | Q43247466 | ||
| Nanosilver toxicity: ions, nanoparticles--or both? | Q46133852 | ||
| Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity | Q46567543 | ||
| How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop | Q47581027 | ||
| The prophylactic use of antibiotics in cell culture | Q47744147 | ||
| In vitro tests to evaluate immunotoxicity: a preliminary study. | Q48645944 | ||
| Comparative eco-toxicity of nanoscale TiO2, SiO2, and ZnO water suspensions. | Q51125822 | ||
| Are in vitro tests suitable for regulatory use? | Q51810641 | ||
| Nanotoxicology: a personal perspective. | Q52597834 | ||
| Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies | Q56483155 | ||
| What's new in Nanotoxicology? Brief review of the 2007 literature | Q57010116 | ||
| A strategy to reduce the use of fish in acute ecotoxicity testing of new chemical substances notified in the European Union | Q58384370 | ||
| Testing strategies for the safety of nanoparticles used in medical applications | Q58680954 | ||
| Streamlined chemical tests rebuffed | Q58930493 | ||
| P433 | issue | 6 | |
| P921 | main subject | nanomaterial | Q967847 |
| P304 | page(s) | 545-573 | |
| P577 | publication date | 2011-07-15 | |
| P1433 | published in | Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology | Q24056192 |
| P1476 | title | Alternative in vitro assays in nanomaterial toxicology | |
| P478 | volume | 3 |
| Q64072100 | A high throughput imaging database of toxicological effects of nanomaterials tested on HepaRG cells |
| Q48119346 | Adoption of in vitro systems and zebrafish embryos as alternative models for reducing rodent use in assessments of immunological and oxidative stress responses to nanomaterials |
| Q47410600 | Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities? |
| Q46819740 | Antioxidant and antigenotoxic properties of CeO2 NPs and cerium sulphate: Studies with Drosophila melanogaster as a promising in vivo model. |
| Q38123394 | Assessing nanoparticle toxicity in cell-based assays: influence of cell culture parameters and optimized models for bridging the in vitro-in vivo gap. |
| Q38075542 | Bridge over troubled waters: understanding the synthetic and biological identities of engineered nanomaterials |
| Q46722489 | Characterization of physicochemical properties of nanomaterials and their immediate environments in high-throughput screening of nanomaterial biological activity |
| Q28394673 | Comprehensive In Vitro Toxicity Testing of a Panel of Representative Oxide Nanomaterials: First Steps towards an Intelligent Testing Strategy |
| Q28074825 | Critical review of the current and future challenges associated with advanced in vitro systems towards the study of nanoparticle (secondary) genotoxicity |
| Q42823163 | Cytotoxicity and morphological transforming potential of cobalt nanoparticles, microparticles and ions in Balb/3T3 mouse fibroblasts: an in vitro model |
| Q58493065 | Elucidating the Potential Biological Impact of Cellulose Nanocrystals |
| Q52737030 | Genotoxicity of cobalt nanoparticles and ions in Drosophila. |
| Q42367089 | Green Toxicology: a strategy for sustainable chemical and material development |
| Q92535762 | In Vitro Research Reproducibility: Keeping Up High Standards |
| Q42828584 | Interaction with culture medium components, cellular uptake and intracellular distribution of cobalt nanoparticles, microparticles and ions in Balb/3T3 mouse fibroblasts. |
| Q58701299 | Multilayered Cultures of NSCLC cells grown at the Air-Liquid Interface allow the efficacy testing of inhaled anti-cancer drugs |
| Q36082067 | NanoE-Tox: New and in-depth database concerning ecotoxicity of nanomaterials |
| Q28383691 | New approach to investigate the cytotoxicity of nanomaterials using single cell mechanics |
| Q92345127 | Perspectives on In Vitro to In Vivo Extrapolations |
| Q28392291 | Sparking connections: toward better linkages between research and human health policy-an example with multiwalled carbon nanotubes |
| Q64922300 | Suitability of 3D human brain spheroid models to distinguish toxic effects of gold and poly-lactic acid nanoparticles to assess biocompatibility for brain drug delivery. |
| Q38112504 | Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines |
Search more.